Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400

Trial meets primary objective of demonstrating safety and tolerability over 12-week treatment period
IMO-8400 also demonstrates clinical proof-of-concept in psoriasis

Idera Pharmaceuticals, Inc. (IDRA) today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400.

Medicure Reports Financial Results for the Third Quarter Fiscal 2014

Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH) (MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2014.

Financial Results

Net revenue from the sale of AGGRASTAT finished product for the three months ended February 28, 2014 increased by 266% to $1.6 million from $447,000 for the three months ended February 28, 2013.

The increase in revenue for the three months ended February 28, 2014 compared to the same period in the prior year is primarily attributable to an increase in the number of new hospital customers using AGGRASTAT, which is driving an overall increase in hospital and wholesale demand.